Oryzon Genomics has announced that it has enrolled the first patient into its collaborative Phase II trial investigating the use of its lead LSD1 inhibitor, iadademstat, in the treatment of relapsed and refractory (r/r) high-grade neuroendocrine carcinomas (NECs). The trial will be conducted in collaboration with the Fox Chase Cancer Center, a leading investigational cancer institute in the US, with Oryzon providing funding, iadademstat and technical advice. In our view, the first patient enrolm ....
18 Jan 2023
Oryzon Genomics - First Phase II patient enrolled is clinical milestone
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Oryzon Genomics - First Phase II patient enrolled is clinical milestone
- Published:
18 Jan 2023 -
Author:
Soo Romanoff -
Pages:
2
Oryzon Genomics has announced that it has enrolled the first patient into its collaborative Phase II trial investigating the use of its lead LSD1 inhibitor, iadademstat, in the treatment of relapsed and refractory (r/r) high-grade neuroendocrine carcinomas (NECs). The trial will be conducted in collaboration with the Fox Chase Cancer Center, a leading investigational cancer institute in the US, with Oryzon providing funding, iadademstat and technical advice. In our view, the first patient enrolm ....